Accueil
Détail de l'auteur
Documents disponibles écrits par cet auteur (13)
Ajouter le résultat dans votre panier Faire une suggestion Affiner la recherche
Article : Périodique
L. VAN SELM ; T. M. WHITE ; C. A. PICCHIO ; A. REQUENA-MENDEZ ; M. BUSZ ; I. BAKKER ; D. ROMERO ; R. PEREZ GAYO ; A. POUILLE ; W. VANDERPLASSCHEN ; J. V. LAZARUS |Background: The number of migrants in the European Union (EU) has been growing, including migrants at risk of using drugs. Little information is available on the actual drug use among first-generation migrants who use drugs in the EU, nor on the[...]
Article : Périodique
J. GREBELY ; B. HAJARIZADEH ; J. V. LAZARUS ; J. BRUNEAU ; C. TRELOAR ; International Network on Hepatitis in Substance Users |There have been major strides towards the World Health Organization goal to eliminate hepatitis C virus (HCV) infection as a global public health threat. The availability of simple, well-tolerated direct-acting antiviral therapies for HCV infect[...]
Article : Périodique
R. BIELEN ; S. R. STUMO ; R. HALFORD ; K. WERLING ; T. REIC ; H. STÖVER ; G. ROBAEYS ; J. V. LAZARUS |Background: Current estimates suggest that 15% of all prisoners worldwide are chronically infected with the hepatitis C virus (HCV), and this number is even higher in regions with high rates of injecting drug use. Although harm reduction service[...]
Article : Périodique
C. BROUARD ; J. PILLONEL ; P. SOGNI ; A. CHOLLET ; J. V. LAZARUS ; X. PASCAL ; F. BARIN ; M. JAUFFRET-ROUSTIDE |People who use drugs (PWUD) are a key population for hepatitis B virus (HBV) vaccination and screening. We aimed to estimate the seroprevalence of HBs antigen (HBsAg) and self-reported HBV vaccination history in French PWUD attending harm reduct[...]
Article : Périodique
J. M. PERICAS ; D. J. BROMBERG ; D. OCAMPO ; E. SCHATZ ; I. WAWER ; P. WYSOCKI ; K. SAFREED-HARMON ; J. V. LAZARUS |Background: In the context of the WHO’s 2016 Viral Hepatitis Strategy and the introduction of treatment that can cure more than 95% of cases with hepatitis C virus (HCV) infection, the European Joint Action on HIV and Co-infection Prevention and[...]
Article : Périodique
L. WIESSING ; M. FERRI ; B. GRADY ; M. KANTZANOU ; I. SPERLE ; K. J. CULLEN ; EMCDDA DRID Group ; A. HATZAKIS ; M. PRINS ; P. VICKERMAN ; J. V. LAZARUS ; V. D. HOPE ; C. MATHEI |Background: People who inject drugs (PWID) are a key population affected by hepatitis C virus (HCV). Treatment options are improving and may enhance prevention; however access for PWID may be poor. The availability in the literature of informati[...]
Article : Périodique
L. WIESSING ; M. FERRI ; V. BELACKOVA ; P. CARRIERI ; S. R. FRIEDMAN ; C. FOLCH ; K. DOLAN ; B. GALVIN ; P. VICKERMAN ; J. V. LAZARUS ; V. MRAVCIK ; M. KRETZSCHMAR ; V. SYPSA ; A. SARASA-RENEDO ; A. UUSKULA ; D. PARASKEVIS ; L. MENDAO ; D. ROSSI ; N. VAN GELDER ; L. MITCHESON ; L. PAOLI ; C. DIAZ GOMEZ ; M. MILHET ; N. DASCALU ; J. KNIGHT ; G. HAY ; E. KALAMARA ; R. SIMON ; C. M. COMISKEY ; C. ROSSI ; P. GRIFFITHS ; EUBEST working group |Background and aims: Despite advances in our knowledge of effective services for people who use drugs over the last decades globally, coverage remains poor in most countries, while quality is often unknown. This paper aims to discuss the histori[...]
Rapport
WHO Regional Office for Europe ; UNAIDS = ONUSIDA ; S. MATIC ; J. V. LAZARUS ; S. NIELSEN ; LAUKAMM-JOSTEN U. | Copenhagen : WHO Regional Office for Europe | 2008The Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia, signed in February 2004, is a key European document on HIV/AIDS. It sets out 33 actions for governments to undertake as related to leadership, prevention, living[...]![Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs [Commentary]](https://bdoc.ofdt.fr/thumbnail.php?type=1&id=79380)
Article : Périodique
J. GREBELY ; J. BRUNEAU ; J. V. LAZARUS ; O. DALGARD ; P. BRUGGMANN ; C. TRELOAR ; M. HICKMAN ; M. HELLARD ; T. ROBERTS ; L. CROOKS ; H. MIDGARD ; S. LARNEY ; L. DEGENHARDT ; H. ALHO ; J. BYRNE ; J. F. DILLON ; J. J. FELD ; G. FOSTER ; D. GOLDBERG ; A. R. LLOYD ; J. REIMER ; G. ROBAEYS ; M. TORRENS ; N. WRIGHT ; I. MAREMMANI ; B. L. NORTON ; A. H. LITWIN ; G. J. DORE ; International Network on Hepatitis in Substance Users |Globally, it is estimated that 71.1 million people have chronic hepatitis C virus (HCV) infection, including an estimated 7.5 million people who have recently injected drugs (PWID). There is an additional large, but unquantified, burden among th[...]Nouveauté
![Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses [Viewpoint]](https://bdoc.ofdt.fr/thumbnail.php?type=1&id=79379)
Article : Périodique
J. V. LAZARUS ; K. SAFREED-HARMON ; S. R. STUMO ; M. JAUFFRET-ROUSTIDE ; M. MATICIC ; T. REIC ; E. SCHATZ ; J. TALLADA ; M. HARRIS ; HEP-CORE STUDY GROUP |In 2016, the World Health Organization (WHO) called for the elimination of viral hepatitis as a public health threat and established the ambitious targets of achieving an 80% reduction in new infections and a 65% reduction in deaths from hepatit[...]
Bulletin : Périodique
International Journal of Drug Policy, Vol.72 - October 2019 - Striving towards the elimination of HCV infection among PWID
J. GREBELY, Éditeur scientifique ; C. TRELOAR, Éditeur scientifique ; J. BRUNEAU, Éditeur scientifique ; J. V. LAZARUS, Éditeur scientifique ; B. HAJARIZADEH, Éditeur scientifique | 2019
Article : Périodique
Hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and liver cancer, is curable in most people. Injecting drug use currently accounts for 80 % of new HCV infections with a known transmission route in the European Union (EU).[...]
Bulletin : Périodique
BMC Infectious Diseases, Vol.14, Suppl.6 - 19 September 2014 - Viral hepatitis and drug use in Europe
J. V. LAZARUS, Éditeur scientifique ; K. A. FENTON, Éditeur scientifique | 2014
